Lunai Bioworks Identifies Three Parkinson's Disease Subtypes And Drug Targets To Accelerate Therapeutic Development In $13B Market

Lunai Bioworks (NASDAQ:LNAI), an AI-powered biotechnology company developing precision therapeutics, today announced the identification of three clinically relevant Parkinson's disease subtypes and prioritized drug targets that may accelerate proof-of-concept programs, derisk therapeutic development, and enable strategic co-development partnerships in a growing $13 billion market.